Press release
Plaque Psoriasis Market Detailed Industry Report Analysis 2025-2034
Plaque Psoriasis Market
Plaque psoriasis is the most common type of psoriasis, accounting for nearly 80-90% of all cases worldwide. It is a chronic autoimmune skin disorder characterized by red, inflamed, and scaly plaques that significantly impair physical comfort, social interactions, and emotional well-being.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71345
Historically, treatments included topical corticosteroids, phototherapy, and systemic drugs. However, the market has been reshaped by the arrival of biologics, JAK/TYK2 inhibitors, and biosimilars, offering long-term efficacy and improved quality of life. With the growing prevalence of autoimmune diseases, patient advocacy, and expansion of personalized dermatology, the global plaque psoriasis market is poised for strong growth through 2034.
Market Overview
• Market Size 2024: USD 24 billion
• Forecast 2034: USD 37 billion
• CAGR (2025-2034): 5.1%
The plaque psoriasis market is expected to grow steadily, supported by adoption of IL-17 and IL-23 inhibitors, increasing use of small-molecule therapies, and affordability through biosimilars. Digital dermatology platforms and AI-based monitoring tools are further expanding patient engagement.
Leading Players include: AbbVie, Novartis, Eli Lilly, Johnson & Johnson, Amgen, Pfizer, Bristol Myers Squibb, UCB, and Sun Pharma.
Segmentation Analysis
By Product
• Biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors)
• Small Molecules (JAK inhibitors, TYK2 inhibitors)
• Conventional Systemics (Methotrexate, Cyclosporine, Acitretin)
• Topical Agents (Corticosteroids, Vitamin D Analogs, Calcineurin Inhibitors)
• Biosimilars
• Supportive Care Medications
By Platform
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies
By Technology
• Biologic & Biosimilar Development Platforms
• JAK/TYK2 Inhibitor Development
• AI-Powered Dermatology & Digital Monitoring Tools
• Precision Medicine & Biomarker Diagnostics
By End Use
• Hospitals & Dermatology Clinics
• Specialty Immunology Centers
• Academic & Research Institutes
• Homecare Settings
By Application
• Mild Plaque Psoriasis
• Moderate Plaque Psoriasis
• Severe Plaque Psoriasis
Summary:
Biologics dominate the plaque psoriasis landscape, particularly IL-17 and IL-23 inhibitors, while TYK2 inhibitors represent the fastest-growing oral therapy class. Biosimilars are expanding affordability, especially in Europe and Asia-Pacific.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71345/plaque-psoriasis-market
Regional Analysis
North America
• Largest market with widespread adoption of biologics and TYK2 inhibitors.
• U.S. leads in FDA approvals, reimbursement support, and digital dermatology adoption.
Europe
• Strong presence with EMA-approved biologics and broad biosimilar adoption.
• Germany, France, and the UK remain leading contributors.
Asia-Pacific
• Fastest-growing region, supported by rising prevalence, healthcare investment, and biosimilar launches in China, India, and Japan.
Middle East & Africa
• Gradual growth as dermatology infrastructure improves, though biologic access remains limited due to affordability.
Latin America
• Moderate growth led by Brazil and Mexico, supported by increasing availability of biosimilars and biologics.
Regional Summary:
North America and Europe dominate the current market, while Asia-Pacific is projected to post the fastest CAGR through 2034, owing to demographics, healthcare expansion, and affordability of biosimilars.
Market Dynamics
Key Growth Drivers
• Rising global prevalence of plaque psoriasis and related comorbidities.
• Increasing adoption of biologics, JAK inhibitors, and TYK2 inhibitors.
• Biosimilar launches improving affordability worldwide.
• Digital health platforms enabling long-term patient engagement.
Key Challenges
• High costs of biologics and novel small molecules.
• Variability in treatment response and relapse risks.
• Limited specialist availability in low-income regions.
Latest Trends
• FDA/EMA approvals of IL-23 and TYK2 inhibitors.
• Growth of biosimilar competition in Europe and Asia.
• Expansion of teledermatology and AI-driven skin monitoring apps.
• Combination regimens under investigation for improved efficacy.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71345
Competitor Analysis
Major Players in the Market:
• AbbVie - Leading with Humira and Skyrizi (IL-23 inhibitor).
• Novartis - Strong presence with Cosentyx (IL-17 inhibitor).
• Eli Lilly - Expanding share with Taltz (IL-17 inhibitor).
• Johnson & Johnson - Tremfya (IL-23 inhibitor) and Stelara (IL-12/23 inhibitor).
• Amgen - Strong in biosimilars and biologics.
• Pfizer - Expanding JAK/TYK2 inhibitor pipeline.
• Bristol Myers Squibb - Innovator with deucravacitinib (TYK2 inhibitor).
• UCB - Focused on dermatology biologics.
• Sun Pharma - Major generics and biosimilar supplier.
Competitive Dynamics:
The plaque psoriasis market is highly competitive, with AbbVie, Novartis, and Eli Lilly dominating biologics. BMS and Pfizer are driving momentum in small-molecule innovation, while biosimilar competition is reshaping affordability and access.
Conclusion
The plaque psoriasis market is undergoing significant transformation, driven by biologics, small molecules, and biosimilars. Despite affordability and access challenges, the market outlook through 2034 remains highly positive.
Key Takeaways:
• Market projected to grow at a CAGR of 5.1% (2025-2034).
• IL-17 and IL-23 inhibitors dominate, while TYK2 inhibitors are the fastest-growing.
• North America and Europe lead adoption, while Asia-Pacific is the fastest-growing region.
• Digital health platforms and biosimilars expand affordability and patient access.
• Competition is focused on biologics pipelines, biosimilar launches, and AI-driven dermatology tools.
Overall, the plaque psoriasis market presents strong opportunities for pharma leaders, biotech innovators, and healthcare providers to advance dermatology care and improve long-term patient outcomes.
This report is also available in the following languages : Japanese (プラーク乾癬市場), Korean (플라크 건선 시장), Chinese (斑块性银屑病市场), French (Marché du psoriasis en plaques), German (Markt für Plaque-Psoriasis), and Italian (Mercato della psoriasi a placche), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71345/plaque-psoriasis-market#request-a-sample
Our More Reports:
Actinic Keratosis Market
https://exactitudeconsultancy.com/reports/71368/actinic-keratosis-market
Androgenetic Alopecia Market
https://exactitudeconsultancy.com/reports/71370/androgenetic-alopecia-market
Bullous Pemphigoid Market
https://exactitudeconsultancy.com/reports/71372/bullous-pemphigoid-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plaque Psoriasis Market Detailed Industry Report Analysis 2025-2034 here
News-ID: 4163659 • Views: …
More Releases from Exactitude Consultancy
Adult-Onset Still's Disease Market to Hit USD 2.5 Billion by 2034
Adult-Onset Still's Disease (AOSD) is a rare systemic autoinflammatory disorder characterized by spiking fevers, arthritis, rash, and elevated inflammatory markers. While its exact cause remains unknown, AOSD is thought to result from dysregulated immune responses involving interleukin (IL)-1, IL-6, and other inflammatory pathways.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71305
Historically, management relied on NSAIDs, corticosteroids, and immunosuppressants, but the past decade has seen major advances with biologic therapies…
Moderate Psoriasis Market Growth, Applications, Innovations and Business Outlook …
Introduction
Psoriasis is a chronic autoimmune skin condition that accelerates the life cycle of skin cells, leading to red, scaly plaques that cause itching, discomfort, and psychosocial distress. Moderate psoriasis represents a significant disease burden-it is more severe than mild cases yet not as extensive as severe psoriasis, making treatment strategies diverse and evolving.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71341
Management of moderate psoriasis historically relied on topical corticosteroids,…
Larynx Cancer Market to Reach USD 3.4 Billion by 2034
Larynx cancer, a type of head and neck cancer, develops in the tissues of the larynx (voice box). It is often linked to risk factors such as tobacco and alcohol use, human papillomavirus (HPV) infection, and occupational exposures. Symptoms like persistent hoarseness, throat pain, and difficulty swallowing often lead to delayed diagnoses, resulting in advanced-stage presentations.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71229
The global larynx cancer market is…
Moderate to Severe Psoriasis Market Growth, Trends, Consumer Demand and Key Oppo …
Introduction
Psoriasis is a chronic, immune-mediated skin disorder marked by red, scaly plaques that can cause significant physical discomfort and psychological burden. Among the different types, moderate to severe psoriasis requires systemic therapy or biologics due to its extensive nature and comorbidities, such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71343
Historically, management involved topical corticosteroids, phototherapy, and systemic drugs like methotrexate or…
More Releases for TYK2
Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline 2025: FDA Updates, Therapy Innovati …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical…
Emerging Trends Influencing The Growth Of The Kinase Inhibitors Market: Advances …
The Kinase Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Kinase Inhibitors Market Size Expected to Be by 2034?
The kinase inhibitors market will grow from $62.75 billion in 2024 to $67.57 billion in 2025, reflecting a CAGR of 7.7%. Growth…
TYK2 Kinase Inhibitors Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, …
(Albany, USA) "TYK2 Kinase Inhibitors Pipeline Insight, 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the TYK2 Kinase Inhibitors Therapeutics Market.
As per DelveInsight's assessment, about 15+ prominent pharma and biotech giants are working on 15+ drugs in the TYK2 Kinase Inhibitors pipeline landscape globally.
The TYK2 Kinase Inhibitors pipeline report provides a detailed description of the pipeline drugs, including the mechanism…
Key Trends Shaping the Future Kinase Inhibitors Market From 2025-2034: Advances …
What Is the Estimated Market Size and Growth Rate for the Kinase Inhibitors Market?
In the past few years, there has been a significant increase in the market size of kinase inhibitors. This market is set to expand from $62.75 billion in 2024 to $67.57 billion in 2025, marking a compound annual growth rate (CAGR) of 7.7%. The historical growth can be linked to numerous factors including the rise in cancer…
Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Assessment, 2023 Updates | In-depth …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and…
Non Receptor Tyrosine Protein Kinase TYK2 Market Share Will Gain Hugh Momentum b …
In recent years, the Global Non Receptor Tyrosine Protein Kinase TYK2 Market has witnessed significant growth and is expected to continue to do so during the forecast period 2023-2030. This report aims to provide a comprehensive analysis of the market's critical aspects, including its strengths, weaknesses, opportunities, and threats. With the help of SWOT and Porter's Five Forces analysis, we will explore the different players operating in the market and…
